Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.30 |
| ▸ | GRM8 | O00222 | 1/20 | 0.30 |
| ▸ | GRM6 | O15303 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9101243 | 0.79 | CA1 (0.39) | CA1CA2CA9 | |
| SCHEMBL8412575 | 0.79 | CA1 (0.33) | CA1CA2CA9INPPL1AKT1 | |
| SCHEMBL29137529 | 0.79 | CA1 (0.39) | CA1CA2CA9 | |
| SCHEMBL3487751 | 0.79 | INPPL1 (0.48) | CA1CA2CA9HSD17B10INPPL1 | |
| SCHEMBL7074278 | 0.74 | — | — | |
| SCHEMBL3073156 | 0.74 | — | — | |
| SCHEMBL28944366 | 0.73 | CA1 (0.30) | CA1CA2CA9 | |
| SCHEMBL3081363 | 0.73 | CA1 (0.30) | CA1CA2CA9 | |
| SCHEMBL13280560 | 0.73 | CA1 (0.36) | CA1CA2CA9 | |
| SCHEMBL28491120 | 0.71 | FDPS (0.39) | INPPL1AKT1INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282803-A1 | DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4511381-A1 | DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Rome Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119403815-A | Didehydro-3 '-deoxy-4' -ethynyl thymidine and related compounds and their use in treating medical conditions | 罗梅治疗股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-111194217-B | 4 '-fluoro-2' -methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | 里伯赛恩斯有限责任公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023205786-A1 | DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3042910-B1 | 2'-SPIRO-NUCLEOSIDES FOR USE IN THE THERAPY OF HEPATITIS C | GILEAD PHARMASSET LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9394331-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| EP-3042910-A2 | 2'-SPIRO-NUCLEOSIDES FOR USE IN THE THERAPY OF HEPATITIS C | Gilead Pharmasset LLC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8841275-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2646453-A1 | COMPOUNDS | Gilead Pharmasset LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075140-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142626-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142626-A1 | COMPOUNDS | HAVCR2, EIF2AK2, NTPCR | CA1 4700/4885CA2 4774/4885CA9 3962/4885 |
| US-20250282803-A1 | DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | DTYMK, DCK, POLK | CA1 4609/4885CA2 4762/4885CA9 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.